Objective To investigate the impacts of Atlas and LVIS Jr stents on the neurological function and cerebral blood perfusion in patients with intracranial aneurysms. Methods One hundred and twenty-eight patients with intracranial aneurysms who received treatment at our hospital from August 2023 to August 2024 were selected as the research subjects. Based on the treatment methods， they were divided into the LVIS Jr stent group （65 cases； 4 cases were lost to follow-up after 12 months， and 61 cases were finally included） and the Atlas stent group （63 cases； 2 cases were lost to follow-up after 12 months， and 61 cases were finally included）. Both groups were followed up until 12 months after the operation. A comparison was made between the two groups in terms of intraoperative instrument performance indicators and adverse events， scores of the NIH Stroke Scale （NIHSS）， scores of the Mini - Mental State Examination （MMSE） （pre-operative， 24 h post-operative， and 7 d post-operative）， Raymond classification （immediately post-operative）， Glasgow Outcome Scale （GOS）， recurrence rates （after 12 months of follow-up）， serum levels of tumor necrosis factor-alpha （TNF-α）， C-reactive protein （CRP）， nerve growth factor （NGF）， and brain-derived neurotrophic factor （BDNF） （pre - operative and 3 d post-operative）， cerebral blood perfusion （pre-operative and 6 months post-operative）， and complication incidence （during the study period）. Results The one-time success rate and good adherence rate of the Atlas stent group were higher than those of the LVIS Jr stent group （P < 0.05）. However， there was no significant difference in the support satisfaction rate and the total incidence of adverse events between the two groups （P > 0.05）. The NIHSS scores in both groups gradually decreased from pre-operative to 7 days after the operation， and the scores in the Atlas stent group were even lower （P < 0.05）. The MMSE scores in both groups gradually increased from pre-operative to 7 days post - operation， particularly in the Atlas stent group （P < 0.05）. Immediately after the operation， the proportion of patients with Raymond Grade Ⅰ in the Atlas stent group was higher than that in the LVIS Jr stent group （P < 0.05）. After 12 months of follow-up， there was no significant difference in the GOS scores between the two groups （P > 0.05）. Compared with the pre-operative levels， the serum levels of TNF-α， CRP， NGF， and BDNF in both groups increased 3 days after the operation. The serum levels of TNF-α and CRP in the Atlas stent group were lower than those in the LVIS Jr stent group， while the serum levels of NGF and BDNF were higher than those in the LVIS Jr stent group （P < 0.05）. Compared with the pre-operative state， the regional cerebral blood volume （rCBV） increased in both groups 6 months after the operation， with a higher value in the Atlas stent group and a lower value in the ICP group （P < 0.05）. During the study period， there was no significant difference in the total incidence of complications between the two groups （P > 0.05）. After 12 months of follow-up， the recurrence rate of the Atlas stent group was lower than that of the LVIS Jr stent group （P < 0.05）. Conclusions Compared with the LVIS Jr stent， the Atlas stent demonstrated superior intraoperative positioning performance and adherent performance during the treatment of intracranial aneurysms. This could enhance the embolization effect， improve cerebral blood flow perfusion， regulate the levels of serum TNF-α， CRP， NGF， and BDNF， promote the recovery of cognitive function and neurological function， and reduce the recurrence rate. In terms of support performance， intraoperative adverse events， long-term prognosis， and risk of complications， the two groups were comparable.